FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 310 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR The art of practicing sustainable science April 22, 2021 A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 EMA Recommends Extension of Indications for Talazoparib November 27, 2023 FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 26, 2024 Load more HOT NEWS Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... Scientists reveal how air pollution can cause lung cancer in people... FDA Approves Avapritinib for Advanced Systemic Mastocytosis ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February
